title: Elevated plasma activator inhibitor 1 is not related to insulin resistance and to gene polymorphism in healthy centenarians.
abstract: Previous studies demonstrated a relationship between the degree of insulin resistance and plasma plasminogen activator inhibitor type-1 (PAI-1) levels. We aim at investigating the relationship between the degree of insulin resistance and plasma PAI-1 levels in aged subjects (n=83) and in healthy centenarians (n=42). In all subjects the degree of insulin resistance was assessed by HOMA method. Our data demonstrated that healthy centenarians have higher plasma PAI-1 levels (73.1+/-13.9 vs 23.7+/-14.7 ng/ml, P<0.001) and lower degree of insulin resistance (1.4+/-0.5 vs 3.3+/-1.3, P<0.001) than aged subjects. In aged subjects plasma PAI-1 levels correlated with the degree of insulin resistance (r=0.61, P<0.001), fasting plasma triglycerides (r=0.74, P<0.001) and age (r=0.33, P<0.001). All such associations were lost in centenarians. Plasma PAI-1 Ag levels were also similar in aged subjects and centenarians even after categorization for PAI gene polymorphism. In multivariate analysis, a model made by age, sex, body mass index, fasting plasma triglycerides, HOMA and PAI-1 gene explained 65 and 50% of plasma PAI-1 level variations in aged subjects and centenarians, respectively. Nevertheless, HOMA (P<0.001) was significantly and independently associated with plasma PAI-1 levels only in aged subjects. In conclusion, our data demonstrates that in healthy centenarians, plasma PAI-1 were not associated with the degree of insulin resistance as in aged subjects. Frequency of PAI-1 genotype does not provide an explanation for such differences between aged subjects and centenarians.
authors.affiliation: Department of Geriatric Medicine and Metabolic Diseases, IV Divisione di Medicina Interna, Second University of Naples, Piazza Miraglia, 2, 80138 Naples, Italy.
authors.forename: Maria Rosaria
authors.initials: MR
authors.lastname: Rizzo
authors.forename: Emilia
authors.initials: E
authors.lastname: Ragno
authors.forename: Michelangela
authors.initials: M
authors.lastname: Barbieri
authors.forename: Domenico
authors.initials: D
authors.lastname: De Lucia
authors.forename: Daniela
authors.initials: D
authors.lastname: Manzella
authors.forename: Maria Rosaria
authors.initials: MR
authors.lastname: Tagliamonte
authors.forename: Donatella
authors.initials: D
authors.lastname: Colaizzo
authors.forename: Maurizio
authors.initials: M
authors.lastname: Margaglione
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Paolisso
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000235:genetics / Q000378:metabolism*; D000933:Antifibrinolytic Agents / Q000097:blood; D000990:Antithrombin III; D015992:Body Mass Index; D005260:Female; D005341:Fibrinolysin; D005838:Genotype; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D010447:Peptide Hydrolases / Q000097:blood; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood* / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012016:Reference Values; D014280:Triglycerides / Q000097:blood; D000979:alpha-2-Antiplasmin
chemical_list: D000933:Antifibrinolytic Agents; D017395:Plasminogen Activator Inhibitor 1; D014280:Triglycerides; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D005341:Fibrinolysin